title: Durable clinical benefit to trastuzumab and chemotherapy in a patient with metastatic colon adenocarcinoma harboring ERBB2 amplification.
abstract: Somatic ERBB2 amplification or activating mutations occur in approximately 2-5% of metastatic colorectal adenocarcinomas and are presumed to be oncogenic drivers, but limited evidence exists to suggest these lesions are sensitive to targeted monotherapy in patients. Here we present the case of a patient with advanced CRC with pulmonary metastases, who had progressed on both standard of care cytotoxic chemotherapy and anti-EGFR targeted therapy. Comprehensive genomic profiling (FoundationOne(®)) identified amplification of ERBB2 and a TP53 mutation in the metastatic lesion. Treatment with trastuzumab with a chemotherapy backbone elicited stable disease/minor response in the patient over a one year course of therapy, reducing tumor burden and significantly improving quality of life. This report demonstrates the application of personalized targeted therapy guided by comprehensive genomic profiling in metastatic colorectal adenocarcinoma.
authors.affiliation: Adana Numune Education and Research Hospital, Department of Medical Oncology, Adana/Turkey.
authors.forename: Umut
authors.initials: U
authors.lastname: Disel
authors.affiliation: Foundation Medicine, Inc. Cambridge, MA, USA.
authors.forename: Alexis
authors.initials: A
authors.lastname: Germain
authors.affiliation: Foundation Medicine, Inc. Cambridge, MA, USA.
authors.forename: Bahar
authors.initials: B
authors.lastname: Yilmazel
authors.affiliation: Baskent University School of Medicine Adana, Turkey.
authors.forename: Huseyin
authors.initials: H
authors.lastname: Abali
authors.affiliation: Baskent University School of Medicine Adana, Turkey.
authors.forename: Filiz Aka
authors.initials: FA
authors.lastname: Bolat
authors.affiliation: Foundation Medicine, Inc. Cambridge, MA, USA.
authors.forename: Roman
authors.initials: R
authors.lastname: Yelensky
authors.affiliation: Foundation Medicine, Inc. Cambridge, MA, USA.
authors.forename: Julia A
authors.initials: JA
authors.lastname: Elvin
authors.affiliation: Foundation Medicine, Inc. Cambridge, MA, USA.
authors.forename: Doron
authors.initials: D
authors.lastname: Lipson
authors.affiliation: Foundation Medicine, Inc. Cambridge, MA, USA.
authors.forename: Juliann
authors.initials: J
authors.lastname: Chmielecki
authors.affiliation: Foundation Medicine, Inc. Cambridge, MA, USA.
authors.forename: Kai
authors.initials: K
authors.lastname: Wang
authors.affiliation: Foundation Medicine, Inc. Cambridge, MA, USA.
authors.forename: Philip J
authors.initials: PJ
authors.lastname: Stephens
authors.affiliation: Foundation Medicine, Inc. Cambridge, MA, USA ; Albany Medical Center, Albany, NY.
authors.forename: Jeffrey S
authors.initials: JS
authors.lastname: Ross
authors.affiliation: Foundation Medicine, Inc. Cambridge, MA, USA.
authors.forename: Vincent A
authors.initials: VA
authors.lastname: Miller
authors.affiliation: Foundation Medicine, Inc. Cambridge, MA, USA.
authors.forename: Siraj M
authors.initials: SM
authors.lastname: Ali
authors.affiliation: University of Florida College of Medicine Gainesville, FL, USA.
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: George
keywords: ERBB2; HER2; colorectal adenocarcinoma; oxaliplatin; trastuzumab